DDInter1851 DDInter1294
Trazodone is triazolopyridine derivative from the serotonin receptor antagonists and reuptake inhibitors (SARIs) class of antidepressants. It is used in adults and has been shown to be comparable in efficacy to other drugs such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine receptor inhibitor (SNRIs) in the treatment of depression. A unique feature of this drug is that it does not promote the anxiety symptoms, sexual symptoms, or insomnia, which are commonly associated with SSRI and SNRI therapy. Trazodone acts on various receptors, including certain histamine, serotonin, and adrenergic receptors, distinguishing it from other antidepressants that cover a narrow range of neurotransmitters. It was initially granted FDA approval in 1981.
Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin that stimulate the growth of normal and malignant prostatic tissue. Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration.
Trazodone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enzalutamide
Enzalutamide {u} (Compound) resembles {v} (Compound) Nilutamide
Trazodone {u} (Compound) causes {v} (Side Effect) Ill-defined disorder
Ill-defined disorder {u} (Side Effect) is caused by {v} (Compound) Nilutamide
Trazodone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enzalutamide
Enzalutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nitisinone
Nitisinone {u} (Compound) resembles {v} (Compound) Nilutamide
Trazodone {u} (Compound) causes {v} (Side Effect) Ill-defined disorder
Ill-defined disorder {u} (Side Effect) is caused by {v} (Compound) Flutamide
Flutamide {u} (Compound) resembles {v} (Compound) Nilutamide
Trazodone {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Flutamide
Flutamide {u} (Compound) resembles {v} (Compound) Nilutamide
Trazodone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enzalutamide
Enzalutamide {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Nilutamide
Trazodone {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is associated with {v} (Disease) prostate cancer
prostate cancer {u} (Disease) is treated by {v} (Compound) Nilutamide
Trazodone {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) interacts with {v} (Gene) POR
POR {u} (Gene) is bound by {v} (Compound) Nilutamide
Trazodone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enzalutamide
Enzalutamide {u} (Compound) is included by {v} (Pharmacologic Class) Androgen Receptor Antagonists
Androgen Receptor Antagonists {u} (Pharmacologic Class) includes {v} (Compound) Nilutamide
Trazodone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enzalutamide
Enzalutamide {u} (Compound) causes {v} (Side Effect) Upper respiratory tract infection
Upper respiratory tract infection {u} (Side Effect) is caused by {v} (Compound) Nilutamide
Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide (Compound) resembles Nilutamide (Compound)
Trazodone (Compound) causes Ill-defined disorder (Side Effect) and Ill-defined disorder (Side Effect) is caused by Nilutamide (Compound)
Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Nitisinone and Nitisinone (Compound) resembles Nilutamide (Compound)
Trazodone (Compound) causes Ill-defined disorder (Side Effect) and Ill-defined disorder (Side Effect) is caused by Flutamide (Compound) and Flutamide (Compound) resembles Nilutamide (Compound)
Trazodone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Flutamide (Compound) and Flutamide (Compound) resembles Nilutamide (Compound)
Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Nilutamide (Compound)
Trazodone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is associated with prostate cancer (Disease) and prostate cancer (Disease) is treated by Nilutamide (Compound)
Trazodone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) interacts with POR (Gene) and POR (Gene) is bound by Nilutamide (Compound)
Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide (Compound) is included by Androgen Receptor Antagonists (Pharmacologic Class) and Androgen Receptor Antagonists (Pharmacologic Class) includes Nilutamide (Compound)
Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide (Compound) causes Upper respiratory tract infection (Side Effect) and Upper respiratory tract infection (Side Effect) is caused by Nilutamide (Compound)